Projects per year
A trial update confirms improved survival for prophylactic elective nodal irradiation and addition of erlotinib to definitive chemoradiotherapy in oesophageal squamous cell carcinoma (ESCC). High tumour EGFR protein expression shows promise to identify those who will benefit from erlotinib. This represents therapeutic progress, and has wider relevance for precision medicine strategies in ESCC.
- Oesophageal cancer
FingerprintDive into the research topics of 'Combining precision medicine and prophylaxis in oesophageal squamous cell carcinoma'. Together they form a unique fingerprint.
- 2 Active